Enhancing the QUAlity and Transparency Of health Research
In support of World Cancer Day we have, today, launched the EQUATOR Oncology Project Quarterly Current Awareness Bulletin.
The bulletin aims to help keep clinicians and researchers working in oncology research up-to-date with the latest issues regarding reporting and methods in oncolocgy research by highlighting links to interesting research papers, editorials, comments and other resources related to cancer research.
To sign up to receive this email bulletin please email Shona Kirtley, firstname.lastname@example.org
EQUATOR Oncology Project Quarterly Current Awareness Bulletin – February 2016
Maillet D, Gan HK, Blay JY, You B, Péron J. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review. Eur J Cancer. 2016;52:26-32. PMID: 26630531
Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. Ann Oncol. 2016;27(1):192-198. PMID: 26483049
Outcomes and endpoints
Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16(1): e32-42. PubMed ID: 25638553
Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K, Kaye S, Parmar MK, Sydes MR, Tannock IF, Oza AM. Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol. 2015; 16(1): e43-52. PubMed ID: 25638556
Saad ED, Buyse M2. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2015. pii: mdv562. [Epub ahead of print]. PMID: 26578738
Korn EL, Sachs MC, McShane LM. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer. Ann Oncol. 2016;27(1):10-15. PMID: 26489443
Barton S, Peckitt C, Sclafani F, Cunningham D, Chau I. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. Eur J Cancer. 2015;51(18):2732-2739. PMID: 26608121
Cuzick J. Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. Ann Oncol. 2015;26 (12):2363-2366. PMID: 26433395
Quality of life
Schandelmaier S, Conen K, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, Amstutz A, Bengough T, Meerpohl JJ, Stegert M, Olu KK, Tikkinen KA, Neumann I, Carrasco-Labra A, Faulhaber M, Mulla SM, Mertz D, Akl EA, Sun X, Bassler D, Busse JW, Ferreira-González I, Lamontagne F, Nordmann A, Gloy V, Raatz H, Moja L, Rosenthal R, Ebrahim S, Vandvik PO, Johnston BC, Walter MA, Burnand B, Schwenkglenks M, Hemkens LG, Bucher HC, Guyatt GH, Briel M, Kasenda B; DISCO study group. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2016;27(1):209. PMID: 26612098
Koller M, Warncke S, Hjermstad MJ, Arraras J, Pompili C, Harle A, Johnson CD, Chie WC, Schulz C, Zeman F, van Meerbeeck JP, Kulis D, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and the EORTC Lung Cancer Group. Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.Cancer. 2015;121(24):4300-4323. PMID: 26451520
Balch CM, Nelson H, Niederhuber JE. Surgery: Limitations of prospective surgical oncology trials – a US view. Nat Rev Clin Oncol. 2016;13(1):6-8. PMID: 26598945
Evrard S, McKelvie-Sebileau P, van de Velde C, Nordlinger B, Poston G. What can we learn from oncology surgical trials? Nat Rev Clin Oncol. 2016;13(1):55-62. PMID: 26483296
Spencer KR, Mehnert JM. Importance of including patients with comorbidities in clinical trials. Lancet Oncol. 2016;17(1):17-18. PMID: 26758750
Nayan M, Jayalath VH, Jewett MA, Bedard PL, Hamilton RJ. Randomized controlled trials in testicular cancer: A demographic and quality assessment. Urol Oncol. 2016;34(2):60.e7-60.e13. PMID: 26493448
Gardner EE, Rudin CM. Drug therapy: Preclinical oncology – reporting transparency needed. Nat Rev Clin Oncol. 2016;13(1):8-9. PMID: 26667971
Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Eur J Cancer. 2015;51(17):2501–2507. PMID: 26338195
Ellis LM. The erosion of research integrity: the need for culture change. Lancet Oncol. 2015;16(7):752-754. PMID: 26149871
Booth CM, Tannock I. Reflections on medical oncology: 25 years of clinical trials–where have we come and where are we going? J Clin Oncol. 2008;26(1):6-8. PubMed ID: 18165630
Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol. 2008;26(33):5458-5464. PubMed ID: 18955452
Browse the oncology-specific reporting guidelines currently available.
Visit the EQUATOR Oncology Project web page for further information about the project and other interesting and useful references.
In a previous post detailing my time with the EQUATOR Network, I spoke about my work on the STrengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. STROBE is one of the original “core” reporting guidelines which provides guidance...